Shopping Cart
Remove All
Your shopping cart is currently empty
ZT-1a is a SPAK inhibitor.ZT-1a inhibits SPAK.ZT-1a can be used for the prevention and treatment of neurodegenerative and neurocognitive disorders.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $74 | In Stock | In Stock | |
| 5 mg | $179 | In Stock | In Stock | |
| 10 mg | $289 | In Stock | In Stock | |
| 25 mg | $397 | In Stock | In Stock | |
| 50 mg | $569 | In Stock | In Stock | |
| 1 mL x 10 mM (in DMSO) | $198 | In Stock | In Stock |
| Description | ZT-1a is a SPAK inhibitor.ZT-1a inhibits SPAK.ZT-1a can be used for the prevention and treatment of neurodegenerative and neurocognitive disorders. |
| In vitro | ZT-1a inhibits the Na-K-2Cl cotransporter (NKCC1) and stimulates the K-Cl cotransporter (KCC) by reducing its SPS1-related proline/alanine-rich kinase (SPAK) dependent phosphorylation[1].At 1 μM ZT-1a, NKCC1 p-Thr203/207/212 phosphorylation is inhibited by 72±5.2%, and in HEK-293 cells, KCC phosphorylation at sites 1/2 is inhibited by 65-77% at 3 μM ZT-1a[1].Phosphorylation of SPAK at the Ser373 site is inhibited by 70±3.8% at 3-10 μM ZT-1a[2]. ZT-1a (10 μM) inhibits NKCC1 but stimulates KCC3 activity[2]. |
| In vivo | ZT-1a inhibits the SPAK-dependent upregulation of NKCC1 and KCC3 phosphorylation in ischemic brains.post-stroke treatment with ZT-1a protects both gray and white matter tissues in ischemic brains[1]. |
| Molecular Weight | 445.73 |
| Formula | C22H15Cl3N2O2 |
| Cas No. | 212135-62-1 |
| Smiles | Cc1cc(C(C#N)c2ccc(Cl)cc2)c(Cl)cc1NC(=O)c1cc(Cl)ccc1O |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||
| Solubility Information | DMSO: 8 mg/mL (17.95 mM), Sonication is recommended. | ||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 1 mg/mL (2.24 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | ||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||
DMSO
| |||||||||||||||||||||
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.